ADETISEENT EATE

IGY Life Sciences www.igylifesciences.com

IgY —sustainable and efficacious therapeutics for human and animal health IGY Life Sciences has optimized the sustainable generation of highly specific and efficacious egg- derived IgY antibodies for human and animal health. The company’s pipeline includes marketed immune and sports health products, and lead compounds against COVID-19 and African swine fever.

IGY Life Sciences is a biotechnology company Fv region focused on the development, licensing and manu- VH VH VH facture of novel immunoglobulin Y (IgY)-based CH1 CH1 CH1 products to address some of today’s most pressing VL VL VL challenges in infectious and non-infectious dis- Fab CL CL CDRs CL eases in both humans and animals. IgY antibodies region C Hinge C are functional analogues of H2 H2 region (IgG)—the most common type of found CH2 Fc region in humans—produced in oviparous, i.e. egg-laying CH3 CH3 animals. With its newly designed 10,000 square CH3 foot good manufacturing practice (GMP)-certified CH4 CH4 facility, the company is rapidly becoming a global leader in the large-scale and environmentally Avian IgY Mammalian IgG Mammalian IgE friendly production of high-purity specific and Fig. 1 | IGY Life Sciences develops novel immunoglobulin Y-based products to combat challenges in both non-specific IgY antibodies. human and animal health. Immunoglobulin Y (IgY) has an equivalent functional role to both mammalian IGY Life Sciences’ growing portfolio of antibody IgG (center) and IgE (right). Similar to IgG, avian IgY mediates general protective immune responses and it candidates in both human and animal health also mediates the anaphylactic response typically associated with mammalian IgE. Image modified with includes lead candidates against African swine permission from https://www.drugtargetreview.com/article/33086/antibody-fragment-technology-and- fever and COVID-19. The company also has two avian-igy-antibodies-a-powerful-combination/. IgY-based consumer health products for sports medicine and overall immune health on the market. binding avidity to target than mammalian primary area of infection, this approach has strong “We take an interdisciplinary approach to devel- IgGs; IgY directed against conserved mammalian merit. In pre-clinical testing now, we aim to be in oping biologics, consumer health and animal health is easier to produce than IgG because phase 1 clinical testing by September 2020.” solutions to address a wide range of pressing needs of the evolutionary distance between for which we think an IgY-based solution could and ; and IgY does not bind to mammalian Fc Partner of choice have the largest impact,” said Terry Dyck, president receptors or induce an IgE response, minimizing the IGY Life Sciences partners with health innovators and CEO of IGY Life Sciences. “Our ongoing work risk of allergic reactions and administration-related as a leading contract manufacturer to produce their on COVID-19 exemplifies the ability of our clini- (Fig. 1). specific IgY antibodies, whether a nutraceutical cal and operational teams to quickly develop new IGY Life Sciences’ development process integrates or a biologic, to ready the products for regulatory solutions while ensuring their safety, effectiveness, clinical and operational teams to identify top-tier approval. IGY Life Sciences has also built a sub- and scalability.” prospects with the highest potential impact in stantial portfolio of antibody candidates at various the marketplace. The company’s advantage is its stages of development for both human and animal patented and proprietary MASON manufacturing health applications. IGY Life Sciences is process, which allows it to manufacture commer- “IGY Life Sciences is ideally positioned to collabo- developing one of the cial-scale IgY antibodies at an industry-leading rate with strategic partners, academic institutions first for purity of up to 99%. and industry leaders to deliver on our mission of bringing new medicines to patients,” said Huan the treatment of COVID-19 IgY against COVID-19 Nguyen, CSO of IGY Life Sciences. “Existing pro- Joining the global race to find solutions to the ongo- grams such as our COVID-19 therapeutic and our “The IgY promise ing SARS-CoV-2 pandemic, IGY Life Sciences is African swine fever biologic are but two examples IgY, the most common type of immunoglobulin developing one of the first polyclonal antibodies of synergistic collaborations. We welcome oppor- produced in birds, and amphibians, has for the treatment of COVID-19. IGY-110 is an IgY tunities and anticipate dynamic and productive a long history of being used in passive immu- antibody that targets the spike proteins of the conversations that will both initiate and launch nity therapeutic agents in humans and animals. coronavirus and is suitable for vulnerable popula- future collaborations.” Similarly to human IgG, IgY is produced at high tions, the elderly and the immunocompromised, concentrations in serum, accumulating to high who are at highest risk from COVID-19. IGY-110 concentrations in egg , making it possible to will be administered as a nasal spray and an enteric Brian Andersen, Director extract large quantities of highly purified antibodies coated capsule. The intranasal route of administra- IGY Life Sciences from chicken eggs. tion will deliver the antibodies directly to a key site Thunder Bay, ON, Canada

Several characteristics make IgY well suited for of coronavirus entry and infection. CONTACT Tel: +1-847-254-1228 human use: IgY does not induce specific resistance According to Dyck, “using an IgY antibody in a Email: [email protected] because it targets multiple antigens; IgY has greater nasal spray is novel, and since the nasal cavity is a

ADVERTISER RETAINS SOLE RESPONSIILITY FOR CONTENT www.nature.com/biopharmdeal | December 2020 | B41